Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewRemacemide hydrochloride is an non-competitive NMDA receptor antagonist; blocks ion channel and allosteric modulatory site (IC50 = 8 - 68 mM). Remacemide hydrochloride is anticonvulsant in vivo and metabolizes to a more potent desglycine analog. Weakly blocks voltage-dependent Na+ channels (IC50 = 161 mM). In an animal model of Huntington's disease, extends survival and delays disease; this effect is more pronounced when combined with Coenzyme Q10 (Cat. No. 3003)
Sold with the permission of AstraZeneca UK Ltd.
M. Wt | 304.82 |
Formula | C17H20N2O.HCl |
Storage | Desiccate at RT |
Purity | ≥99% (HPLC) |
CAS Number | 111686-79-4 |
PubChem ID | 60510 |
InChI Key | HYQMIUSWZXGTCC-UHFFFAOYSA-N |
Smiles | Cl.CC(CC1=CC=CC=C1)(NC(=O)CN)C1=CC=CC=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Palmer et al (1995) Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride. Ann.N.Y.Acad.Sci. 765 236 PMID: 7486610
Santangeli et al (2002) Na+ channel effects of remacemide and desglycinyl-remacemide in rat cortical synaptosomes. Eur.J.Pharmacol. 438 63 PMID: 11906711
Subramaniam et al (1996) Block of the N-MthD.-aspartate receptor by remacemide and its des-glycine metabolite. J.Pharmacol.Exp.Ther. 276 161 PMID: 8558426
Ferrante et al (2002) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J.Neurosci. 22 1592 PMID: 11880489
Keywords: Remacemide hydrochloride, Remacemide hydrochloride supplier, NMDA, antagonists, blocks, ion, channel, allosteric, modulatory, site, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, AstraZeneca, FPL, 12924AA, 1622, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for Remacemide hydrochloride.
There are currently no reviews for this product. Be the first to review Remacemide hydrochloride and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.